CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine. The end-product, adenosine, has both tumor-promoting and immunosuppressive effects. The aim of this study was to determine CD73 expression on immune cells in pleural effusion (PE) in order to have a better understanding of the immune environment in mesothelioma. PE-or blood-derived CD14+ cells of mesothelioma patients and healthy donors were analyzed by flow cytometry for the expression of CD39 and CD73. CD73-induction was studied by exposure of CD14+ cells to the soluble fraction of PE (sPE), while the signaling mechanism, responsible for CD73 induction, by phosphoflow cytometry and receptorinhibition studies. We observed CD73 expression on CD14+ cells in PE but not peripheral blood of mesothelioma patients or healthy donors. CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine. Inhibition of PGE2 receptors or adenosine A2 receptors blocked CD73-induction by sPE. sPE treatment triggered protein kinase A and p38 activation. However, signal-transducer and activator of transcription 3 (STAT3)-blocking led to enhanced CD73 expression, demonstrating a hitherto unknown negative control of purinergic signaling by STAT3 in CD14+ cells. TNFα production by CD73 + CD14+ cells was significantly impaired in the presence of AMP, confirming immunosuppressive function.
Introduction
Solid tumors have much higher levels of extracellular ATP and adenosine than normal tissues. 1 ATP represents a danger signal via binding to P2 purinoreceptors, such as P2X7 on leukocytes, contributing to inflammation. This signaling has been reported to have tumor suppressor effects, and, interestingly, P2X7 levels are lower in cancer than in normal tissues. 2 Conversely, the ATPmetabolite adenosine has extensive immunosuppressive effects 3, 4 via binding to a range of adenosine-receptors present on most immune cells. 5 ATP conversion into ADP and 5'-AMP is catalyzed by CD39, while AMP is hydrolyzed by CD73 to adenosine. In the tumor microenvironment, the CD39/CD73/adenosine axis contributes not only to immunosuppression but also directly supports tumor growth, differentiation, metastasis and angiogenesis. 2, 6, 7 .
Cell surface co-expression of CD39 and CD73 ensures rapid ATP uptake from the pericellular environment leading to topical generation of adenosine. 1 Double positive cells or extracellular vesicles, such as exosomes 8 , can act as efficient enzyme-delivery systems reaching distant sites. The co-expression of these enzymes on immune cells has been demonstrated for activated mouse Treg and Th17 cells 9, 10 but untreated human Tregs in the circulation only express low levels of intracellular CD73. 11 Mouse peritoneal macrophages may also coexpress these enzymes, 12 while healthy non-activated human blood monocytes and macrophages have abundant expression of CD39 but not CD73 on the cell surface. 13, 14 Ectonucleotidase expression can be controlled by the microenvironment; e.g. CD39 expression is regulated by IL-27 in ovarian cancer, 15 while CD73 is upregulated by hypoxia on epithelial cells 16 , by TGFβ on murine leukocytes 17 and by signal-transducer and activator of transcription-3 (STAT3) activation on murine Th17 cells. 10 Endothelial cells were observed to respond to increased intracellular cAMP levels via an adenosine-mediated paracrine pathway leading to CD73 upregulation. 18 The aim of this study was to reveal whether immune cells in the pleural effusion (PE) of MPM express CD73.
Malignancy-associated PE is a relatively easily accessible material in MPM. It is a complex milieu that reflects some of the characteristics of the tumor and represents a rich source of tumor and immune cells and soluble factors. PE is responsible for indirectly influencing tumor cells, regulating inflammation and contributing to tumor dissemination. 19 The population of CD14+ cells in the tumor microenvironment consists of tumor-associated macrophages and monocytes. In mesothelioma, M2 macrophages with immunosuppressive features have been observed in the tumor; their ratio (CD163/CD68) having a negative prognostic value. 20 The effect of sPE on skewing macrophage differentiation into M2 type has recently been demonstrated, 21, 22 however, CD73 expression has not been studied on these cells.
We report here the presence of CD39/CD73 co-expressing CD14 + cells in the PE of patients with MPM. When healthy donor peripheral blood mononuclear cells (PBMC) were exposed to the cell-free, soluble fraction of PE (sPE), surface expression of CD73 was induced in a dose-and cell type-dependent manner on CD14 + but not on CD3 + cells. The effect of sPE on CD73 induction was mimicked by cAMP-inducing agents, such as forskolin or PGE2, or with adenosine, in a protein kinase A (PKA)-and p38-dependent manner. Conversely, sPE-induced CD73 expression was significantly amplified by inhibiting STAT3 phosphorylation. We demonstrate that CD73, induced on CD14+ cells, is functional, as its activity suppresses TNFα production. These observations point towards a cross-talk between cAMP/adenosine and STAT3 signaling in the regulation of CD73 expression on monocytes in the tumor microenvironment, offering novel treatment targets in MPM.
Results

CD73 is expressed on CD14+ cells in mesothelioma-associated PE.
The aim of our study was to explore whether tumor-associated immune cells co-express CD39 and CD73. The cellular fraction of PE from MPM patients was phenotyped and the frequencies of those CD14 + or CD3 + cells that co-expressed CD39 and CD73 were determined and compared with frequencies found in patients' or healthy donors' PBMC. We found CD73 expression on CD14 + cells in PE but not in blood ( Fig. 1A upper panel) . The mean frequency of CD39 + CD73 + double positive CD14+ cells was 17.4% in the PE of three donors ( Fig. 1B ) compared to <0.5% in PBMC ( Figure 1B ). CD39 was expressed at comparable levels on CD14+ cells in healthy or patient PBMC (mfi: 455 and 547), while in PE its expression was more than three-fold higher (mfi: 1,732) ( Fig. 1A upper panel) . CD73 expression levels and co-expression with CD39 were also analyzed on CD3 + cells: The frequency of CD3 + cells expressing CD73 was not elevated in PE compared to that in PBMC ( Fig. 1A , lower panel). These results demonstrate a specific induction of CD73 in the tumor environment on myeloid (CD14+) but not T (CD3+) cells.
Only CD14+ cells in PE co-express CD73 and CD39. Tumor cells have been shown to express CD73 while some also co-express CD39. 23 In order to demonstrate that the CD39 + CD73 + CD14 + cells in PE are distinct from e.g. tumor or mesothelial cells, which are CD14-, CD73 expression on CD3 -CD14 -/FSC high cells(T) vs. CD3 -CD14 + FSC intermediate (M) cells was studied (Fig. 1C ). As expected, the CD14 -FSC high (T; potentially tumor-containing) cell population was only present in the PE and not blood. These cells expressed CD73 but not CD39 and this pattern was similar to that we observed on established primary mesothelioma cell lines 24, 25 (Fig. 1D ). These results prove that CD39 + CD73 + coexpression is a characteristic of CD14+ monocytes/macrophages in MPMassociated PE.
CD73 expression is induced selectively on CD14 + cells by sPE.
In order to determine whether soluble factors in PE are responsible for inducing CD73 expression on CD14+ cells, healthy donor PBMC was exposed to increasing concentrations of sPE for 48h in vitro. Flow cytometry analysis of CD14 + cells demonstrated that CD73 is significantly upregulated by sPE, pooled from four patients, and this upregulation is dose-dependent ( Fig Table 1 ) an additional five sPE samples (individual or pooled) have confirmed the findings (Supplementary Figure 1 ). One sample (sPE9) derived from a patient with sarcomatoid mesothelioma. The induction of CD73 expression was protein-specific, as CD39 expression levels were not altered. It was also cell type specific, as CD39 + CD73 + cell frequencies remained unchanged in the CD3 + subset ( Fig. 2A , lower panel). Phenotyping of sPE-treated CD14 + cells indicated CD14, CD16 and CD163 upregulation, compared to that on untreated cells, while CD62L, CD86 and HLA-DR were expressed at lower levels following sPE-treatment (See Supplementary Fig. 2 .A). We also tested for PDL-1 antigen expression, a marker of immunosuppression, but its level was not enhanced by treatment with sPE, in fact it was downregulated. HLA-DR, CD16 and CD163 expression were lower on CD73 + cells than on CD73 -cells in the sPEtreated group (See Fig. S2 .B). The results indicate that soluble factors in PE have a significant and selective effect on inducing CD73 expression on CD14 + cells, however, CD73 + CD14 + cells do not express typical M2 macrophage markers.
PGE2 induces CD73 expression on CD14 + cells.
As CD73 was only expressed on MPM patients' CD14 + cells in the PE but not in blood, we analyzed the differences in cytokine composition of PE vs. plasma. A cytokine array revealed that sPE contained elevated levels of IL-6, IL-8, IL-13, IP-10 and MCP-1 ( Fig. S3 ) compared to plasma, while ELISA experiments demonstrated that hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1 (SDF-1) levels were also higher in sPE than in plasma ( Fig. 2B ). Next we tested the concentration of PGE2 in the pooled sPE used in the experiments: PGE2 concentration was more than two-fold higher in the sPE than in MPM plasma ( Fig. 2B last panel) . On the other hand, we did not find elevated TGFβ levels in PE compared to that in plasma by TGFβ ELISA ( Fig   2B) . We then screened a variety of cytokines for their ability to induce CD73expression on monocytes. We found that IL-6, IL-8, HGF, VEGF and SDF, alone or in combination ( Fig 2C) , or TGFβ alone (not shown) or in combination with IL-6 and IL-10 failed to induce CD73 expression ( Fig. 2D ). However, when CD14 + cells were treated with 100 ng/ml PGE2 for 48h, significant induction of CD73 expression was observed ( Fig. 2E) . In order to demonstrate that PGE2 in sPE is a relevant factor that can drive CD73 induction, G-protein coupled E-type prostanoid receptors, EP2 and EP4, that have been demonstrated to be the main PGE2 receptors present on human monocytic cells 26 , were blocked before exposing CD14 + cells to sPE. The near complete inhibition of CD73 expression ( Fig 2E) confirmed that PGE2 in sPE plays a dominant role in the induction of CD73 on human CD14+ cells. PGE2 is a known inducer of intracellular cAMP. 27 Thus, next we tested if cAMP is involved in CD73 induction, by stimulation with forskolin, which is a receptor-independent, pharmacological inducer of intracellular cAMP. Indeed, forskolin proved efficient in inducing CD73 expression on healthy donor CD14 + cells (Fig. 2F ), confirming the role of cAMP signaling in CD73 upregulation.
Adenosine can also induce CD73 expression on CD14+ cells.
Extracellular adenosine is a relevant factor in supporting mesothelioma, as we show it in a tumor cell growth support experiment, where NECA significantly enhanced primary mesothelioma cell line proliferation ( Fig. S4 ). As adenosine, signaling via the A2A receptor, has also been shown to induce intracellular cAMP 28 , we tested the effect of the adenosine analogue NECA on CD73 expression. We found significant CD73 induction on CD14 + cells by NECA ( Fig.   3A ). To confirm the relevance of this observation in our PE study, we blocked A2A adenosine receptor before CD14 + cells were exposed to sPE. A partial, but significant prevention of CD73 induction was observed both at 24h and 48h ( Fig.   3B ). The results show that the adenosine pathway triggers the induction of CD73 surface expression on CD14 + cells, generating a potentially self-amplifying autocrine loop.
CD73 is induced on CD14 + cells by sPE via PKA and p38 signaling.
As cAMP is known to signal via PKA and p38, we tested whether exposure of CD14 + cells to sPE activates this pathway. First we pre-treated the cells with the PKA inhibitor H-89. Upon sPE-or PGE2-treatment, CD73 upregulation was significantly inhibited (Fig. 3C ) by the PKA inhibitor. The phosphorylation of p38 after exposure of monocytes to sPE was also tested. p38 activation was elevated as early as 10 min, compared to untreated cells, and gradually decreased by 4h ( Fig. 3D ). Anisomycin (antibiotic, known to activate p38), used as a positive control, displayed slightly slower kinetics of p38 phosphorylation ( Fig. 3D ).
Inhibition of p38 phosphorylation with the small molecule inhibitor SB203580
was also carried out, and it completely abolished CD73 upregulation either by sPE or NECA (Fig. 3E ). These results demonstrate that CD73 expression can be induced on CD14+ cells by PGE2 and adenosine, soluble factors relevant in cancer, and this induction can be mimicked by forskolin via the cAMP/PKA/p38signaling pathway.
CD73 induction on CD14 + cells by sPE is enhanced by STAT3
inhibition. In mouse Treg cells, STAT3 activation contributed to the upregulation of CD73. 10 In order to explore the role of this pathway in the induction of CD73 expression on human monocytes, we tested if sPE-treatment triggers STAT3 phosphorylation. Exposure of CD14 + cells to sPE indeed resulted in significant STAT3 phosphorylation at 30 min, with sustained kinetics, as it was still significantly elevated at 2h and 4h compared to that in untreated cells (Fig.   4A ). In order to explore the consequences of STAT3 activation, we inhibited STAT3 phosphorylation with the small molecule inhibitor Cpd188 in cells exposed to sPE, at a concentration we have established previously. 29 Unexpectedly, in the presence of the inhibitor, sPE-mediated induction of CD73 expression became significantly enhanced (Fig. 4B ). sPE did not activate STAT1 and Cpd188 had no off-target effects on this transcription factor ( Fig 4C, left panel). These results indicate that STAT3 exerts a negative effect on CD73 induction and thus it may have the ability to curb excessive adenosine production. This was confirmed by an experiment where IL-6 was added together with sPE or NECA to CD14 + cells. In combination with sPE, IL-6 had no effect on CD73 induction ( Figure 4D ), presumably because IL-6 was already present at elevated levels in the sPE (as shown on Fig S3) . However, when added with NECA, CD73 induction was significantly inhibited by IL-6. The negative regulation of adenosinergic signaling in human monocytes/macrophages by STAT3 represents a novel (i.e. a non-immunosuppressive) role for STAT3 in the immune regulation of cancer.
sPE-induced CD73 on CD14 + cells is functional.
Finally, we determined if CD73, upregulated by sPE on CD14 + cells, is able to impair the function of these cells. Highly purified, healthy peripheral blood CD14 + cells were treated with sPE overnight. Adenosine A2A and A2B receptor-inhibitors were added to the cells, followed by AMP and LPS. TNFα production was assessed by intracellular cytokine staining ( Fig. 4E ). Adding AMP to these cells resulted in a nearly 50% inhibition of LPS-induced TNFα production. In the presence of adenosine receptor inhibitors, AMP's negative effect on cytokine production was prevented, proving that the inhibition is adenosine-mediated. Adenosine receptor inhibitors, added to CD14 + cells in the presence of LPS but without AMP, resulted in a small but significant increase in TNFα production, presumably due to a low level of adenosine being intrinsically present in the cultures. These experiments provide evidence that CD73, induced by sPE, partakes in the generation of local immunosuppression in mesothelioma in an adenosine receptor-mediated manner. The suggested mechanism of positive and negative regulation of CD73 expression is summarized on Fig. 5 .
Discussion
This study shows that mesothelioma-associated PE has a regulatory role in the purinergic pathway by inducing the expression of CD73 on myeloid cells. CD73 is a rate-limiting enzyme in the hydrolysis of ATP to adenosine. We demonstrate its induction on CD14 + cells by sPE in a PGE2-or adenosine-dependent manner, via cAMP, PKA and p38 signaling. As a functional consequence, pro-inflammatory cytokine production is impaired by CD73-expressing CD14 + cells in the presence of AMP; this impairment is reversible by A2 receptor-inhibitors.
Human monocytes and macrophages are largely CD73 negative but express CD39. 13 Although CD73 upregulation has been reported on other cell types, such as on T cells, epithelial cells 30 , endothelial cells 18 and murine leukocytes, 17 such an observation has only recently been made on human macrophages in ovarian cancer. 31 We have reported earlier that tumor cells may be present in mesothelioma PE 24 and here we demonstrate that these tumor cells in PE may express CD73 but not CD39. Co-expression of CD73 and CD39, which is only observed on CD14 + cells in PE but not in blood, makes these tumorassociated macrophages (TAM) a key cell type in purinergic regulation. CD39/CD73 double positive TAM have the potential of reducing extracellular ATP levels by hydrolysis, leading to the generation of adenosine, which then helps in maintaining a tumor-supporting and immunosuppressive microenvironment. We observed that sPE skews monocytic differentiation towards M2-like macrophages, as detected via CD14 and CD163 upregulation and downregulation of HLA-DR. This confirms recent findings on the effect of MPM-PE on macrophages 21, 22 . However, CD14 + cells, which are also positive for CD73, are phenotypically distinct from M2-like cells as their CD163 expression level is significantly lower than that on CD73 -cells and there are no differences in CD14 expression levels. Thus we conclude that CD73 induction is distinct from CD14 + cell differentiation towards M2-like macrophages. PDL-1 expression was also downregulated or remained low on these cells, which may not be surprising as PDL-1 induction is the consequence of type I and II interferon stimulation 32 , while in the tumor milieu, myeloid cells predominantly encounter antiinflammatory factors.
Extracellular adenosine is elevated in numerous cancer tissues 1 with direct tumor-promoting effects, and indirect, immunosuppressive functions, by inhibiting effector T cells or promoting regulatory T cell activity. 6, 33 In mesothelioma, high concentration of extracellular adenosine (3 mM) has been reported to cause apoptosis of tumor cells. 34 However, we show here that physiological concentrations support tumor growth, indicating the relevance of adenosine in the progression of this disease.
We demonstrate in this study that PGE2 induces the expression of CD73 on monocytes. PGE2 is the main product of COX2 and COX2-overexpression is a negative prognostic factor in MPM. 35 PGE2 has recently been identified at elevated concentrations in MPM-PE. 22 It has been suggested that PGE2 is a potential factor to induce immunosuppressive M2 macrophages, however, mechanistic data have been lacking to support this. PGE2 has been shown to increase cAMP levels via prostanoid receptors EP2/EP4. We demonstrate here that CD73 upregulation on CD14 + cells by sPE is blocked by inhibiting its receptors, EP2 and EP4, confirming the role of PGE2 in the regulation of the adenosinergic pathway in mesothelioma. PGE2 has also been shown to impair purinergic signaling by ATP in macrophages 36 , which suggests that in the presence of PGE2, extracellular ATP is preferentially undergoing hydrolysis by myeloid cells. cAMP signals via PKA and p38, and this signaling has been shown to suppress the production of TNFα and IFNγin keratinocytes. 37 We demonstrate here that sPE activation of the cAMP-PKA-p38 pathway leads to CD73 induction on the surface of human CD14 + cells, as small molecule inhibitors of PKA and p38 prevent CD73 induction. As CD73 enzyme activity results in the generation of adenosine, which induces further CD73 expression on myeloid cells, we describe a self-amplifying loop here which may be similar to the immunosuppressive autocrine adenosinergic loop described for Treg cells. 9 When testing STAT3 activation in CD14+ cells exposed to sPE, we found simultaneous phosphorylation of p38 and STAT3. STAT3 can be activated by IL-6, IL-10 or VEGF; adenosine can mediate STAT3 activation via IL-10, as demonstrated in mouse macrophages 38 , while PGE2 itself has also been shown to phosphorylate STAT3 in cardiomyocytes. 39 Signaling via STAT3 can upregulate CD73 in Th17 cells. 10 However, when STAT3 was blocked in our model, instead of inhibition of CD73 upregulation, we observed significantly enhanced CD73 expression. There is no known inhibitory influence of STAT3 on cAMP signaling; however, a possible explanation is that there may be a competition for CREB binding protein (CBP) between cAMP-activated CREB and STAT3. Thus, inhibition of STAT3 may favor CREB binding, similar to what has been shown in the human myeloid THP cell line. 40 We are currently investigating this regulatory effect of STAT3 on CD73 expression.
Taken together, we demonstrate here that PGE2 in mesotheliomaassociated PE regulates CD73 expression on CD14 + cells in a cAMP-mediated manner, while STAT3 acts as a negative regulator of this process. A2A-receptor inhibition has been shown to synergize with the effect of PDL-1 immune checkpoint inhibitors in preclinical tumor models 41 
Materials and Methods
Blood, PE and cell lines. Ethical approval for the study was granted by the South-East Wales Research Ethics Committee. Venous blood was collected from healthy donors or MPM patients. PE samples were collected into sterile containers attached to indwelling catheters. Patient characteristics are described in Table 1 . sPE stock was prepared from four donors and used throughout these experiments. The sPE fraction was prepared by depleting cells (centrifugation at 2,000 rpm for 20min), filtering the supernatant (0.22μm) and storing aliquots at Negative regulation by pSTAT3 was demonstrated by a STAT3-inhibitor (5) . CD14 + cells were incubated for 48h in the presence or absence of 12.5% sPE. Cell surface labeling was carried out on ice for 30min using antibodies specific for CD3, CD14, CD16, CD86, HLA-DR, PDL-1, CD1c, CD62L, CD163 and CD73 (Affymetrix) and (BD-Biosciences). A FACSVerse cytometer (BD-Biosciences) was used for cell phenotyping, and FACSDiva software for data analysis. Figure S1 . CD73 is upregulated on CD14+ cells by MPM PE. Means+SD of CD73 or isotype mean fluorescence intensity (mfi) from triplicate samples are shown following 48h treatment with (A) Nil, or 50% of 75% sPE pooled from three donors, or (B) with nil and sPE from a further 6 individual donors. The Mix from samples 4-7 represents the pooled sPE from donors as listed in Table 1 of the main paper, and used in all experiments. sPE9 represents a sample from a patient with sarcomatoid subtype of mesothelioma. 
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